佐他莫司|T6033|TargetMol

Zotarolimus
221877-54-9

￥553 1mg 起订

￥793 2mg 起订

￥1230 5mg 起订

上海更新日期：2024-12-12

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 佐他莫司

英文名称：: Zotarolimus

CAS号：: 221877-54-9

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: ≥98%

产品类别：: 抑制剂

货号：: T6033

Product Introduction

Bioactivity

名称	Zotarolimus
描述	Zotarolimus (ABT-578), an analogue of rapamycin, inhibits FKBP-12 (IC50= 2.8 nM).
细胞实验	Cell proliferation is assayed by measuring tritiated thymidine incorporation in vitro. Human coronary artery cells (hCa) are seeded into tissue culture flasks for expansion and applied to 96-well plates at desired density in complete media (5000 hCaSMC; 10 000 hCaEC). After 2 days, complete media is replaced with incomplete media to synchronize cells and induce G0 state. Two days later, incomplete media are removed and replaced with complete media (serum/growth factors) to induce G0 to G1 transition. Complete media also contain drug at desired concentrations to determine its effects on cell proliferation. On day 7, 3H-thymidine is added to cells to monitor DNA synthesis, and cells are harvested after overnight incorporation of radioactivity. After an incubation period of 72 h, 25 μL (1 μCi/well) of 3H-thymidine are added to each well. The cells are incubated at 37°C for 16-18 h to allow for incorporation of 3H-thymidine into newly synthesized DNA and the cells harvested onto 96-well plates containing bonded glass fibre filters . The filter plates are air-dried overnight, MicroScint-20 (25 μL) added to each filter well and counted. Drug activity is determined by the inhibition of 3H-thymidine incorporation into newly synthesized DNA relative to cells grown in complete media. (Only for Reference)
激酶实验	zotarolimus (10 pM-1 μM) in buffer A (2% BSA and 0.2% Tween-20 in D-PBS) is used in the assay of Binding Affinity to FKBP12.
动物实验	Male Sprague-Dawley rats was administrate by intravenous or oral Zotarolimus（2.5 mg/kg）dissolved inethanol: propylene glycol: cremophor EL: D5W vehicle (20: 30: 2: 48, by volume).
体外活性	在平滑肌细胞（IC50=2.9 nM）和内皮细胞（IC50=2.6 nM）中，Zotarolimus有效抑制细胞增殖。
体内活性	Zotarolimus 强效抑制剂，对辅助性迟发型超敏反应(DTH)(ED50=1.72 mg/kg/day)、实验性自身免疫性脑炎(EAE)(ED50=1.17 mg/kg/day)、以及心脏移植排斥反应(ED50=3.71 mg/kg/day)表现出显著的抑制作用。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	Ethanol : 93 mg/mL (96.3 mM) DMSO : 93 mg/mL (96.3 mM) H2O : < 1 mg/mL (insoluble or slightly soluble)
关键字	coronary \| ABT 578 \| drug-eluting \| inhibit \| artery \| disease \| restenosis \| Rapamycin \| Zotarolimus \| ABT578 \| immunosuppressant \| A-179578 \| stents \| A179578 \| Inhibitor
相关产品	α-Hydroxyglutaric Acid Lithium \| P-2281 \| Capivasertib \| Rapamycin \| Bimiralisib \| L-Leucine \| GDC0084 \| Tacrolimus \| Dihydromyricetin \| PI3K/Akt/mTOR-IN-2 \| Sapanisertib \| (+)-Usnic acid
相关库	经典已知活性库 \| 已知活性化合物库 \| 激酶抑制剂库 \| 抗衰老化合物库 \| 药物功能重定位化合物库 \| 抗癌临床化合物库 \| 抗癌药物库

咗他莫司|||佐他莫司|||ABT-578|||A 179578|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务